MARKET

GLUE

GLUE

Monte Rosa Therapeutics, Inc.
NASDAQ
11.77
+0.05
+0.43%
After Hours: 11.77 0 0.00% 19:30 09/25 EDT
OPEN
11.75
PREV CLOSE
11.72
HIGH
11.89
LOW
11.62
VOLUME
802.14K
TURNOVER
--
52 WEEK HIGH
25.77
52 WEEK LOW
6.23
MARKET CAP
1.00B
P/E (TTM)
-6.7601
1D
5D
1M
3M
1Y
5Y
1D
What Monte Rosa Therapeutics (GLUE)'s Phase 2 Trial Start Means For Shareholders
Simply Wall St · 5d ago
Weekly Report: what happened at GLUE last week (0914-0918)?
Weekly Report · 6d ago
Weekly Report: what happened at GLUE last week (0907-0911)?
Weekly Report · 09/14 10:30
Phase 2 Start Might Change The Case For Investing In Monte Rosa Therapeutics Stock (GLUE)
Simply Wall St · 09/09 13:20
Wedbush Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)
TipRanks · 09/09 12:55
Monte Rosa Therapeutics Price Target Maintained With a $27.00/Share by Wedbush
Dow Jones · 09/09 12:22
Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $27 Price Target
Benzinga · 09/09 12:12
Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Monte Rosa Therapeutics (GLUE)
TipRanks · 09/09 11:30
More
About GLUE
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Webull offers Monte Rosa Therapeutics Inc stock information, including NASDAQ: GLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GLUE stock methods without spending real money on the virtual paper trading platform.